Evidence map›Paper›PMID 28213859›Full record

SynthesisCurrent urology reports2017

Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data.

Jacqueline M Speed, Quoc-Dien Trinh, Toni K Choueiri, Maxine Sun

Registry-linked trialAbstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Current urology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07172386 (A Study on the Safety and Efficacy of Super-selective Tumour Arterial Embolisation in Combination With Toripalimab and Axitinib as a Preoperative Treatment for Advanced Renal Cell Carcinoma), which is not on this map. Cited by 56 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 4 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07172386 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

A Study on the Safety and Efficacy of Super-selective Tumour Arterial Embolisation in Combination With Toripalimab and Axitinib as a Preoperative Treatment for Advanced Renal Cell Carcinoma

TypeinterventionalSponsorTianjin Medical University Second HospitalRan2025 to 2027Enrolled40ConditionsRenal Cell Carcinoma (RCC)ArmsToripalimab and axitinib
3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 4 syntheses or guidelines pooled it, 79 citations in OpenAlex.

  1. Guideline
  2. Treatments for renal cell carcinoma: NICE Pilot Treatment Pathways Appraisal.Health technology assessment (Winchester, England) · 2026
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Advances in Adjuvant Therapy for Renal Cell Carcinoma: Perspectives on Risk Stratification and Treatment Outcomes.International journal of urology : official journal of the Japanese Urological Association · 2025
    Review
  17. Article
  18. Navigating advanced renal cell carcinoma in the era of artificial intelligence.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jacqueline M SpeedBrigham and Women's Hospital, 45 Francis St, ASB II-3, Boston, MA, 02115, USA.
Quoc-Dien TrinhBrigham and Women's Hospital, 45 Francis St, ASB II-3, Boston, MA, 02115, USA.
Toni K ChoueiriDana-Farber Cancer Institute, Dana 1230, 44 Binney St., Boston, MA, 02215, USA.
Maxine SunBrigham and Women's Hospital, 45 Francis St, ASB II-3, Boston, MA, 02115, USA. maxinesun@gmail.com.
Brigham and Women's Hospital · USDana-Farber Cancer Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewPatients with localized renal cell carcinoma (RCC) are at risk of recurrence. The purpose of this review was to characterize the literature on recurrence rates and risk factors after diagnosis of localized RCC. RECENT

findingsOur search revealed that existing data examining the prevalence of recurrence rates predominantly originates from cohorts of patients diagnosed and treated in the 1980s to 1990s, and may therefore not be as useful for counseling for current patients today. Many nomograms including the Cindolo Recurrence Risk Formula, the University of California-Los Angeles (UCLA) Integrated Scoring System (UISS), the SSIGN score, the Kattan nomogram, and the Karakiewicz nomogram have shown value in identifying patients at higher risk for recurrence. Biomarkers and gene assays have shown promise in augmenting the predictive accuracy of some of the aforementioned predictive models, especially when multiple gene markers are used in combination. However, more work is needed in not only developing a model but also validating it in other settings prior to clinical use. Adjuvant therapy is a promising new treatment strategy for patients with high-risk disease. Importantly, too many surveillance strategies exist. This may stem from the lack of a consensus in the urological community in how to follow these patients, as well as the variable guideline recommendations. In conclusion, contemporary recurrence rates are needed. Recurrence risk prediction models should be developed based on a series of more contemporary patients, and externally validated prior to routine clinical practice. Surveillance strategies following treatment of localized RCC need to be identified and standardized. Finally, there is a trend toward personalizing surveillance regimens to more appropriately screen patients at higher risk of recurrence.

Indexed as

Carcinoma, Renal CellCombined Modality TherapyHumansKidney NeoplasmsNeoplasm Recurrence, LocalPrognosisRisk FactorsBiomarkers in renal cellLocalized renal cell carcinomaRecurrent renal cell carcinomaRisk factors for renal cell recurrenceSurveillance in renal cellTreatment of localized renal cell carcinoma

Identifiers

PMID28213859
OpenAlexW2588011375

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.